anti-ALK MAb / AstraZeneca - LARVOL DELTA

Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population. (PubMed) - PLoS One - "The incidence rate of ALK gene fusion in Chinese CRC patients was 0.44%,but not detectable in gastric and esophageal cancers. The novel SPTBN1 -ALK fusion, together with other ALK fusion genes, may become a potential target for anti-ALK therapy."

Journal • Biosimilar • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Oncology

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. (PubMed) - Oncotarget - "One patient in whom a new fusion type (EML4->EXOC6B->ALK fusion) was identified obtained a partial response. These findings indicate that patients with ALK-positive lung adenocarcinoma who test Ventana IHC-positive and FISH-negative may still respond to crizotinib therapy."

Journal • Biosimilar • Non Small Cell Lung Cancer • Oncology

ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma. (PubMed) - Chin J Cancer Res - "The ALK gene expression status detected by the Ventana IHC ALK (D5F3) platform in MPE samples may predict tumor responsiveness to crizotinib in Chinese patients with advanced lung adenocarcinoma."

Journal • Biosimilar • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor (WCLC 2016) - "A 40-year-old woman diagnosed with ALK-rearranged PPC experienced a partial response (-32%) to the ALK inhibitor crizotinib.The incidence of anaplastic lymphoma kinase (ALK) rearrangement is controversial, and clinical benefit from anti-ALK treatment in PSC remains unknown.This study aimed to reveal the reliable frequency and the clinical-pathologic characteristics of pulmonary sarcomatoid carcinoma (PSC) with anaplastic lymphoma kinase (ALK) rearrangement, and to provide insight into the translatability of anti-ALK treatment in this treatment-refractory disease. The incidence rates of ALK rearrangement in PSC in the Chinese population are similar to those of other subtypes of NSCLC. PSCs in younger never-smokers are more often to harbor ALK rearrangement. ALK inhibitors may serve as an effective treatment for ALK-rearranged PSC."

Clinical • Biosimilar • Non Small Cell Lung Cancer • Oncology • Sarcoma

Targeted degradation of anaplastic lymphoma kinase by target degraducer in non-small cell lung cancer (ESMO Asia 2016) - "The TDs showed anti-ALK activities in both enzymatic and cell-based assays. LDK-378 (ceritinib) as an ALK ligand and VHL or CRBN as an E3 ubiquitin ligase were selected. Hydroxyproline analogs (HP-7) and pomalidomide were used for VHL and CRBN E3 ligase ligands, respectively. These results suggest that the ALK-TDs, inducing ALK degradation, represents a promising strategy for the treatment of ALK-driven NSCLC."

Preclinical • Biosimilar • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. (PubMed) - "The activities of these compounds were confirmed in both enzyme- and cell-based ALK assays. Amongst compounds synthesized, KRCA-0445 showed very promising results in pharmacokinetic study and in vivo efficacy study with H3122 xenograft mouse model."

Journal • Biosimilar • Oncology

False ALK Rearrangement Signals in Inflammatory Cells: A Pitfall in the Interpretation of ALK Fluorescence In Situ Hybridization in Non-Small Cell Lung Cancer. (PubMed) - Appl Immunohistochem Mol Morphol - "In this technical article, we point out the importance of taking into account both histopathologic and ALK immunohistochemical features to interpret ALK fluorescence in situ hybridization analyses in inflammatory and necrotic tumors. This confrontation is crucial to avoid misdiagnosis and inappropriate therapeutic management."

Journal • Biosimilar • Non Small Cell Lung Cancer • Oncology